CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 25 enrolled
Drug / intervention
vatalanibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00348790
NCT00348790Phase 2Completed
CompareCT.gov

A Phase II Trial of PTK-787 in Recurrent or Progressive Meningiomas

Northwestern University·interventional·Posted Jul 6, 2006·Updated Oct 26, 2018

In Brief

A Phase 2 clinical trial evaluating vatalanib for Brain and Central Nervous System Tumors and Sarcoma. Completed, enrolled 25 participants across 3 sites.

Detailed Summary

RATIONALE: Vatalanib may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well vatalanib works in treating patients with recurrent or progressive meningioma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBrain and Central Nervous System Tumors, Sarcoma
CountriesUnited States
CollaboratorsNovartis

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 6, 2006
Enrollment StartMay 1, 2006
Primary CompletionNov 1, 2010
Study CompletionJul 1, 2013
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 20.0 years ago

Interventions

vatalanibdrug